Where did the development of JPH203 originate?

It originated from Dr. Hitoshi Endo’s research on LAT1 at Kinki University. J-Pharma advanced it into drug development.

Why was biliary tract cancer chosen as the target?

Due to limited treatment options and high unmet medical needs, making it a high-impact indication for new therapies.

What changed with Uniphar’s support?

Strategic regulatory engagement enabled progression to Phase 3 without additional Phase 2 trials.

AI News NQ Analysis

J-Pharma and Uniphar Announce Strategic Partnership Milestone: Global Phase 3 Trial Initiation for JPH203 (nanvuranlat)

Key facts

J-Pharma and Uniphar Announce Strategic Partnership Milestone: Global Phase 3 Trial Initiation for JPH203 (nanvuranlat)
J-Pharma Co., Ltd. and Uniphar have jointly announced the initiation of a global Phase 3 clinical trial for JPH203 (nanvuranlat), a novel LAT1 inhibitor targeting second-line treatment of biliary tract cancer. Following discussions with the FDA, the program has advanced directly to Phase 3 without additional Phase 2 trials, and first patient enrollment and randomization have been completed.
Source: PR TIMES
Date: Tue Jun 16 2026 18:06:01 GMT+0900 (Japan Standard Time)

Direct answer

J-Pharma Co., Ltd. and Uniphar have jointly announced the initiation of a global Phase 3 clinical trial for JPH203 (nanvuranlat), a novel LAT1 inhibitor targeting second-line treatment of biliary tract cancer. Following discussions with the FDA, the program has advanced directly to Phase 3 without additional Phase 2 trials, and first patient enrollment and randomization have been completed.

Citation: J-Pharma and Uniphar Announce Strategic Partnership Milestone: Global Phase 3 Trial Initiation for JPH203 (nanvuranlat) (Tue Jun 16 2026 18:06:01 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Tue Jun 16 2026 18:06:01 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

J-Pharma Co., Ltd. and Uniphar have jointly announced the initiation of a global Phase 3 clinical trial for JPH203 (nanvuranlat), a novel LAT1 inhibitor targeting second-line treatment of biliary tract cancer. Following discussions with the FDA, the program has advanced directly to Phase 3 without additional Phase 2 trials, and first patient enrollment and randomization have been completed.

AI Analysis

Frequently Asked Questions

Q: Where did the development of JPH203 originate?: A: It originated from Dr. Hitoshi Endo’s research on LAT1 at Kinki University. J-Pharma advanced it into drug development.
Q: Why was biliary tract cancer chosen as the target?: A: Due to limited treatment options and high unmet medical needs, making it a high-impact indication for new therapies.
Q: What changed with Uniphar’s support?: A: Strategic regulatory engagement enabled progression to Phase 3 without additional Phase 2 trials.